9995:HKEXRemeGen Co. Ltd. Class H Analysis

RemeGen is trading at HK$71.4, well below its 20‑day SMA of 72.44 and far under the 50‑day (89.18) and 200‑day (89.98) averages, signaling a bearish technical backdrop. However, the MACD line has crossed above its signal (a bullish cue) and the RSI sits at 41, suggesting limited downside and a potential short‑term bounce off the 63.3 support level.
Fundamentally, the company posted a 24.8% YoY revenue surge with an impressive 86.9% gross margin, yet operating margin remains negative and debt‑to‑equity is high at 53%, flagging earnings volatility and leverage risk. Valuation is mixed: a trailing PE of 48x dwarfs the industry average of 24.5x, while the DCF‑derived fair value of HK$56.9 sits below the current price, indicating possible over‑pricing despite analyst targets averaging HK$114. The stock carries no dividend and exhibits a 48% 30‑day volatility, underscoring a high‑risk, high‑reward profile.